
Modern Value Investing: Lessons from Microsoft, Apple, Pfizer, and Merck
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Today, we’re diving into the key insights from the research paper "Value Investing, A Modern Approach."
🔹 Value investing is about finding undervalued companies — stocks that the market has mispriced — and buying them with the belief that their true value will eventually be recognized.
The foundation of this strategy is the concept of intrinsic value — the real worth of a company beyond its current market price.
🔹 Key Strategy:
When choosing between two similar companies, value investors prefer the one trading at a lower price, aiming for a bargain and a margin of safety.
Patience and a long-term perspective are crucial.
📚 Case Study Analysis:
The paper analyzed Microsoft and Apple (tech giants), and Pfizer and Merck (pharma leaders) over four years (2019–2022).
Microsoft & Apple had higher earnings and revenue but slower percentage growth — because they were already huge companies.
Pfizer & Merck, starting smaller, showed faster percentage growth. Pfizer especially surged in revenue during the pandemic due to vaccine development.
Key takeaway:
Smaller, strong companies might offer higher growth potential when bought at the right time.
🎯 Practical Strategies for Traders:
Look for undervalued businesses with strong fundamentals.
Focus on long-term growth, not short-term hype.
Companies with a smaller revenue base can sometimes grow faster.
Compare similar companies and pick the better-priced option.
Stay flexible — value investing must adapt to changes in markets and regulations.